Mandibular exercises improve mandibular advancement device therapy for obstructive sleep apnea

Paulo Afonso Cunali · Fernanda R. Almeida · Camila D. Santos · Natália Y. Valdrichi · Liliane S. Nascimento · Cibele Dal-Fabbro · Sérgio Tufik · Lia Rita A. Bittencourt

Received: 19 April 2010 / Revised: 22 September 2010 / Accepted: 25 September 2010 / Published online: 22 October 2010
© Springer-Verlag 2010

Abstract
Rationale Temporomandibular disorder (TMD) has been the most common contraindication for mandibular advancement device (MAD) as a treatment for obstructive sleep apnea syndrome (OSAS). Exercising the mandible is a recommended form of therapy for TMD.

Objectives To assess the efficacy of mandibular exercises in the control of pain, changes of quality of life and to assess the impact of MAD compliance in OSAS patients with previously diagnosed TMD.

Methods A blind, randomized, and controlled trial was used to evaluate 29 OSAS patients with TMDs were divided in two groups: the exercise support therapy (ST) and placebo therapy (PT), who were evaluated prior to and 120 days after MAD treatment. Treatment outcomes were measured using the Fletcher and Luckett sleep questionnaire, Epworth sleepiness scale, SF-36 inventory of quality of life, polysomnography, diary of MAD usage, and the research diagnostic criteria for TMD.

Measurements and main results ST group showed significant improvement in their sleep quality and life quality when compared to the PT group (p<0.05). Higher number of patients with persistent pain was observed in the PT group (p=0.01). There was a reduction of pain intensity in the ST group, but not in the PT group (p<0.05). Higher MAD compliance was observed in the ST group (p<0.05).

Conclusions Mandibular exercises enable patients with TMD to use MAD; exercises were found to be effective in reducing pain and increasing MAD compliance and produced a significant improvement in the quality of life and quality of sleep.

Keywords Obstructive sleep apnea syndrome · Mandibular advancement device · Oral appliance · Temporomandibular disorders · Mandibular exercises

Introduction
A mandibular advancement device (MAD) is an effective treatment for obstructive sleep apnea syndrome (OSAS) [1, 2]; in addition, it is a noninvasive modality that is reversible and easy to build. It is widely recommended as a treatment for snoring and for mild and moderate OSAS [3, 4]. Such devices are also recommended for mild and moderate OSAS patients who have not responded to continuous positive airway pressure therapy (CPAP), who are not appropriate candidates for CPAP, or whose previous attempts to use the CPAP failed [5]. It has been widely described that the use of MAD may have several short-term side effects, such as excessive salivation, dry mouth, tooth discomfort, pain in the soft tissue within the mouth, and pain or discomfort in the masticatory muscles and/or temporomandibular joints [6–8]. Pain originating either from the masticatory muscles or the temporomandibular joint (TMJ) is referred as a temporomandibular disorder.
(TMD); this pain may be one of the main reasons for poor compliance or abandonment MAD treatment [9–14]. TMD patients most frequently report pain or discomfort in the region of the face. TMD pain can be exacerbated by mandibular function, resulting in limited mouth opening. The condition may produce noise from the temporomandibular joint, headaches, and alterations of sleep quality [15–18]. For pain control and recovery of mandibular function, noninvasive and reversible modalities of treatment are the first choices of treatment [18, 19]. Yet another noteworthy issue is the reduced quality of life endured by with TMD pain [20, 21] which is also seen in OSAS patients. Mandibular exercises, known as support therapy (ST), are used as a treatment modality for TMD. ST is widely accepted by patients and is efficient in the management of muscular and joint dysfunction [22–28].

It is noteworthy that in studies of MAD therapy, different diagnostic criteria have been used to evaluate TMD pain [6–10] and various authors have contraindicated the MAD when any sign of TMD was present [10]. Others have reported noncompliance or suspension of the MAD usage because of the development of TMD related to MAD usage [9–14].

However, to our knowledge, there are no studies which did simultaneously assess therapies controlling TMD pain and MAD treatment. The purpose of this study was to assess the efficacy of support therapy (ST) in the reduction of pain, improvement in the quality of life, and compliance to MAD treatment in OSAS patients with TMD pain.

Methods

Study population

Adult patients diagnosed with mild and moderate OSAS [29], with TMD diagnosed by the Research Diagnostic Criteria (RDC/TMD) [30] adapted and translated to Portuguese [31, 32] and referred for MAD treatment, were assessed in the sleep ambulatory unit of Universidade Federal de Sao Paulo (UNIFESP), Brazil. This experimental investigation had the approval of the Ethics in Research Board of the UNIFESP. The inclusion criteria was adopted for the following indication of MAD described in the literature [4]: age between 18 and 60 years, apnea–hypopnea index (AHI) over 5 and under 30, and body mass index (BMI) less than or equal to 30 kg/m². Both genders were included. Patients, who presented fewer than 10 teeth per arch, active periodontal disease, a need of overall dental treatment, a mandible protrusion less than 5 mm, limited mouth opening, use of alcohol, drugs or hypnotic substances, and sleep disturbances other than OSAS with or without previous treatment for OSAS, were excluded. As cervical myofascial pain can refer pain to the face, patients with cervical myofascial pain were not included in this study.

Study design

This study was a double-blind, randomized, and controlled trial in which patients were distributed into ST and placebo therapy (PT) groups.

To ensure patients were blinded to the study, both therapies were explained to the patients as being effective therapies. The investigator who was blinded to the randomization has only applied all study instruments of evaluation such as the RDC, while a second investigator did the randomization and was responsible for explaining the exercises to the patients. Patients were evaluated at the start of the protocol and after 120 days, according to the experimental design described in Fig. 1. Sleep evaluation was assessed by polysomnography and by the Fletcher and Luckett questionnaire [33]. Sleepiness was measured by the Epworth sleepiness scale (ESS) [34], and the quality of life was assessed by the quality of life inventory (SF-36) [35]. TMD was evaluated by the investigator (PAC) throughout the study, who was also responsible for advancing and adjusting the appliance. The presence and type (persistent or recurring) of TMD pain was assessed after the first week of MAD use, in the week when MAD advancement reached two-thirds of maximum mandible protrusion, and in the week when it reached maximum protrusion. Intensity of pain was assessed prior to and after treatment. Compliance to the treatment was registered 1 week after insertion and after final titration of the MAD by sleep log book. This book of sleep show that the use of MAD throughout the night, part of the night, or when the patient did not using the MAD. These data were also collected by the second investigator blind while the principal investigator (PAC).

The MAD appliance used is the Brazilian repositioning device (BRD®), an adjustable device, made in a specialized laboratory, developed at UNIFESP (Fig. 2a and b). The appliance was inserted at 50% of the maximum mandible protrusion; patients were instructed to return for reevaluation every month and to advance the appliance 0.5 mm/week. This advancement was monitored until the maximum mandible protrusion was achieved.

Outcome measures

Questionnaires

The Fletcher and Luckett [33] questionnaire consists of questions about sleep, snoring, nocturnal apnea, and daytime somnolence. This questionnaire classifies the answers as never (0), rarely (1), occasionally (2), and often
(3) Daytime somnolence was evaluated by the Epworth sleepiness scale [34]. These questionnaires were used to quantify the sleep complaints of patients. To assess patient’s quality of life, we used the quality of life inventory (SF-36) [35] which refers to the subjective quality of life in day-by-day activities, work, pain, and other activities. All three questionnaires were used prior to MAD treatment and after 120 days of the treatment.

**TMD diagnostic**

We employed the “Research Diagnostic Criteria for Temporomandibular Disorders” (RDC/TMD) [30], a tool developed to quantify and qualify signs and symptoms of TMD, to classify TMD. This questionnaire, adapted to Portuguese, has been used previously [31, 32]. It evaluates the presence of pain in the facial region and in the TMJ in the previous 30 days, especially during mandibular function. All patients were asked to fill out the protocol to score their chronic TMD pain; clinical exams for classification and confirmation of TMD were carried out according to the clinical examination for the RDC/TMD. Three sites of pain in the masticatory muscles and/or in TMJ, in the clinic evaluation, coinciding with the same sites of pain complaint by the patient determined the clinical diagnosis [30]. The RDC/TMD was applied before treatment and in the week during which the patients completed 120 days of treatment.

**Polysomnography**

Polysomnography, used for diagnosis and treatment follow-up, consisted of the computerized system Sonolab Meditron (version 2003.a). Surface electrodes were used to record electroencephalographs (EEG; C3-A2, C4-A1, O2-A1, O1-A2); submentonian and tibial electromyograph recordings (EMG); bilateral electrooculograms (EOG); and electrocardiographs (ECG-modified derivation V1). Breathing was monitored with a nasal cannula, in which air flow is gauged by pressure transduction, and oral flow was monitored with a thermal sensor. Thoracic and abdominal movements were

---

**Fig. 1** Model study design. Abbreviations: PSG Polysomnography, F&L Fletcher and Lucket questionnaire, ESS Epworth sleepiness scale, SF36 quality of life inventory (SF-36), RDC Research diagnostic criteria for temporomandibular disorders, MAD mandibular advancement device

**Fig. 2** Brazilian repositioning device (BRD™)
measured with noncalibrated pletismography. Measurements of oxygen saturation were collected from a wrist oxymetry device (Nellcor). The position used for the recordings, lying down, allowed the placement of a sensor over the sternum bone to define body position, and an attached tracheal microphone allowed recording of snoring.

Staging was made according to the directives set forth by Rechtschaffen and Kales [36], and respiratory events were scored following the criteria adopted by the American Academy of Sleep Medicine (AASM) board [37]. Awakenings were scored by the criteria of the American Sleep Disorders Association (ASDA) [38].

Support therapy

Patients were blind to their assigned type of therapy. ST consisted of coordinated exercises to stretch the mandibular muscles, and it was adopted to control pain as well as to restore movement otherwise hampered by TMD pain. For coordinated movements, patients were instructed to perform sequences of exercises by controlled mouth opening. This was achieved by maintaining the tongue in contact with the palate, followed by a sequence of lateral left–right movement of the mandible against light-hand resistance. This type of movement was used with the intent to exercise the lateral pterygoid muscles and the TMJ (Fig. 3a, b, and c). For stretching, we used the movement of opening the mouth against light resistance of the hand, followed by a maximum opening of the mouth assisted by the fingers, with the intent of stretching the temporal and masseter muscles (Fig. 2d and e). Patients were instructed to exercise twice a day, in three sets of five repetitions of each movement, prior to and after use of the MAD. These mandibular exercises, adopted as ST, have proven to be efficient and effective in the treatment of TMD [19]. The patients were highly reinforced to do the exercises on a regular basis, but we could not be sure if patients had followed our recommendations.

Placebo therapy

PT consisted of two different types of assisted cervical movement. At first, the patient was instructed to rotate the head left and right (Fig. 4a and b) and then to tilt the head to each side, recovering the vertical position against the resistance of the hand placed contralaterally (Fig. 4c and d). This type of exercise was chosen because patients had no cervical myofascial pain (muscular cervicalgia), a condition that could point to pain in the face and mimic TMD pain [39]. Patients in the PT group were instructed to perform three sets of five repetitions for each movement, twice a day, prior and subsequent to use of the MAD; this is the same frequency used for the ST group. Although these exercises are indicated for myofascial cervical pain, like we said in the description of study population, patients with cervical myofascial pain were not included in this study.

Treatment outcome

The efficacy of MAD therapy was measured by the Fletcher and Luckett questionnaire, ESS, and polysomnography (PSG). The efficacy of ST in reducing pain intensity was determined by comparing the intensity of pain, in both ST and PT groups at baseline settings and after 120 days of treatment, by the RDC/TMD. We also assessed the occurrence of TMD pain, which was deemed persistent when there was pain at the morning MAD removal and during mastication, preventing the subject from using the MAD that day. When pain or discomfort was reported only during removal of the MAD, without compromising its use or mastication, it was considered recurrent pain.

Changes in quality of life in both groups were determined by comparing the baseline and end-of-protocol results of the SF-36 test. In order to determine what influence ST had in MAD compliance, log books of MAD use of ST adhesion were maintained by the patients.

Statistical analyses

Results are presented means and standard errors. For quantitative comparisons between groups, the Student’s t test for independent samples, or the intra-group Student’s t test for dependent variables, was used. The Chi-squared test was used for the categorical data. For statistical calculations, the software Statistic® 6.0 was used, and the value of p=0.05 was considered as significant.

Results

A total of 45 (52% of 87 patients) with mild to moderate cases of OSAS and referred for MAD therapy presented signs or symptoms of TMD pain. Two patients were excluded by the inclusion criteria, and 11 never returned for the initial assessment. Thus, 32 patients were selected for randomization; 29 completed the protocol.

Comparisons were made between the 14 patients who either did not finish (n=3) or did not accept to participate in the study (n=11) and the 29 patients who completed the protocol. There was no statistical significance between these groups with regard to age (44.5±10.7×49.7±9.8 years), BMI (25.2±3.8×25.9±4.1 kg/m²) or AHI (13.7 5.25×16.5 4.1). At baseline, none of the groups presented any statistically significant differences, except that the PT group was on average younger (Table 1).
The Fletcher and Luckett Sleep questionnaire showed significant changes, related to treatment, only in the ST group (Table 2). Comparison of the SF-36 before and after MAD titration showed a significant improvement in a higher number of quality of life domains in ST group, as compared to PT group (in 5 of the 8 domains in the ST group, and in three of the eight domains for the PT group). Differences were significant in domains related to pain (pain, general health) and psychoemotional aspects (limitation by emotional and mental health; Table 2). We found no difference in polysomnographic parameters between groups at baseline (Table 1); ST and PT groups both showed a significant reduction in their AHIs with the MAD. There was no difference between groups in terms of AHI improvement, but only the ST group presented a significant alteration in the minimum oxygen saturation parameter.

Fig. 3 ST exercises used for coordination and stretching, with the goal to restore the movements function and control pain. For coordination, movements of opening and closing the mouth with tongue limitation (a), and lateral movements against mild hand resistance were directed to the lateral pterygoide muscles and temporomandibular joints (b and c); For stretching, the movement of opening the mouth against hand resistance (d), and the forced assisted movement of widely opening the mouth, forced by fingers (e), gave stretching to temporal and masseter muscles.

Fig. 4 Placebo therapy exercises used with different kinds of assisted cervical movements. First the patient was instructed to rotate the head to the left and to the right sides (a and b), and second to tilt the head sideways forcing the head to the upright position against hand resistance (c and d).
There was no significant difference in the type of complaints of TMD pain in the first week (8 of 15 and 8 of 14 patients in the ST and PT groups, respectively). At two-thirds of the maximum MAD advancement, there was a greater number of patients with persistent pain in the PT group (14 patients) compared to the ST group (three patients). This condition remained for the maximum advancement setting, when a higher number of complaints concerning persistent pain was observed in PT group (ten patients) compared to ST group (four patients; Fig. 5).

By the criteria of the RDC/TMD, the intensity of pain decreased between the baseline and the final condition of the treatment in the ST group, whereas in the PT group, pain was slightly increased, but without significance (Fig. 6).

Compliance to the MAD was similar between groups during the first week. After advancement of the MAD, greater compliance was observed in the ST group (Fig. 7).

### Discussion

This is the first study to assess an ST for TMD pain control in patients who undergo MAD therapy and who have been diagnosed with TMD by RDC/TMD prior to MAD treatment. Patients in the ST group reported less pain, adhered better to MAD therapy, and experienced significant improvements in their quality of life and sleep as compared to patients in the placebo group (PT).

The MAD therapy in the present study resulted in a significant improvement in AHI and a decrease in the number of micro-arousals, regardless of the therapy adopted (ST or PT). The improvements achieved with the use of the MAD confirm the well-established literature demonstrating the efficacy of MAD therapy [5, 11, 14].

The quality of life and quality of sleep in OSAS patients are compromised, and according to some studies, this condition can be improved by MAD treatment [40, 41]. In the present investigation, the sleep complaints assessed by the Fletcher and Luckett questionnaire [33] were reduced only in the ST group. We also found a significant improvement in, and in a higher number of, quality of life domains in the ST group compared with the PT group. Such differences were represented by domains related to pain (pain, general health) and psychoemotional aspects (limitation by emotional and mental health). Although some improvement was expected in both groups after the same treatment was offered to the ST and PT groups, MAD treatment, we hypothesize that persistent pain could be related to the worsening of the quality of sleep. We observed that, independent of group (PT or ST), the excessive daytime sleepiness measured with Epworth sleepiness scale remained high after the treatment with the MAD. Although a significant change in sleepiness after MAD usage has been shown [6, 11, 12, 42], there are other studies that, in agreement with ours, did not find a significant change [1, 43]. The ESS is a subjective measurement tool, and it does not always correlate well

| Table 1 Baseline demographics, sleep, and quality of life questionnaires and polysomnographic data between ST and PT groups |
|-------------------|-------------------|-------------------|
|                    | Placebo therapy   | Support therapy   | p Values |
| Age                | 44±12             | 53±9              | 0.032    |
| BMI (kg/m²)        | 26±4              | 26±4              | NS       |
| Gender (M/F)       | 5/9               | 4/11              | NS       |
| ESS                | 12±6              | 14±6              | NS       |
| FLQ                | 0.4±0.2           | 0.5±0.2           | NS       |
| SF36 FC            | 60±16             | 70±19             | NS       |
| SF36 LPhA          | 32±34             | 54±45             | NS       |
| SF36 PAIN          | 44±21             | 37±20             | NS       |
| SF36 GSH           | 56±24             | 54±21             | NS       |
| SF36 V             | 32±15             | 39±22             | NS       |
| SF36 SA            | 62±30             | 46±25             | NS       |
| SF36 LEA           | 40±40             | 43±44             | NS       |
| SF36 M             | 49±17             | 50±15             | NS       |
| Sleep efficiency (%) | 89±8             | 87±6              | NS       |
| Stages 3 and 4 (%) | 19±5              | 17±6              | NS       |
| REM (%)            | 20±5              | 19±5              | NS       |
| Arousals (h)       | 15±7              | 16±7              | NS       |
| AHI (h)            | 18±10             | 16±8              | NS       |
| MinSatO2 (%)       | 86±4              | 86±4              | NS       |

Differences are defined as p > 0.05

ST Support therapy, PT placebo therapy, BMI body mass index, ESS Epworth sleepiness scale, AHI apnea–hypopnea index, MinSatO2 minimum oxygen saturation, FLQ Fletcher and Luckett questionnaire, SF36 SF 36 inventory for quality of life, FC functional capacity, LPhA limit by physical aspects, PAIN pain, GSH general state of health, V vitality, SA social aspect, LEA limit by emotional aspects, M mental health, NS Not significant, test “t” for independent samples
with objective measures of excessive sleepiness, such as the multiple latency sleep test or the maintenance of vigil test [44]. Because this study did not apply objective measures of sleepiness, we hesitate to conclude that the use of the MAD did not reduce patients’ sleepiness. Another possibility of EDS persistency could be a chronic pain condition with long period of sleep fragmentation leading to alteration in the awake–sleep brain system.

The contraindications of MAD treatment in TMD patients probably originated due to side effects like pain in the TMJ and masticatory muscles caused by MAD use [9, 10, 45]. Such exclusions, however, have been made in the absence of reproducible, systematic diagnostic criteria for TMD. As a result of the present study, we believe that the contraindication of MAD for patients with TMD is not based on proven results, and patients with TMD are still eligible for MAD therapy.

Table 2 Demographics, sleep, and quality of life questionnaires and polysomnographic data between ST and PT groups in baseline and after MAD treatment

<table>
<thead>
<tr>
<th></th>
<th>Placebo therapy</th>
<th></th>
<th>Support therapy</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>With MAD</td>
<td>Baseline</td>
<td>With MAD</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26±4</td>
<td>26±4</td>
<td>26±4</td>
<td>27±4</td>
</tr>
<tr>
<td>ESS</td>
<td>12±6</td>
<td>11±6</td>
<td>14±6</td>
<td>13±7</td>
</tr>
<tr>
<td>FLQ</td>
<td>0.4±0.2</td>
<td>0.4±0.1</td>
<td>0.5±0.2*</td>
<td>0.4±0.1**</td>
</tr>
<tr>
<td>SF36 FC</td>
<td>66±28</td>
<td>66±28</td>
<td>70±19</td>
<td>70±29</td>
</tr>
<tr>
<td>SF36 LPhA</td>
<td>32±34</td>
<td>54±40*</td>
<td>54±45</td>
<td>73±30</td>
</tr>
<tr>
<td>SF36 PAIN</td>
<td>44±21</td>
<td>51±26</td>
<td>37±20</td>
<td>55±22**</td>
</tr>
<tr>
<td>SF36 GSH</td>
<td>54±24</td>
<td>59±20</td>
<td>54±21**</td>
<td>67±23**</td>
</tr>
<tr>
<td>SF36 V</td>
<td>31±15</td>
<td>44±19*</td>
<td>39±22**</td>
<td>51±19**</td>
</tr>
<tr>
<td>SF36 SA</td>
<td>58±29*</td>
<td>76±28*</td>
<td>46±23</td>
<td>66±32</td>
</tr>
<tr>
<td>SF36 LEA</td>
<td>40±40</td>
<td>59±44</td>
<td>43±44*</td>
<td>71±35**</td>
</tr>
<tr>
<td>SF36 M</td>
<td>48±17</td>
<td>57±22</td>
<td>50±16*</td>
<td>65±22**</td>
</tr>
<tr>
<td>MAI (#/h sleep)</td>
<td>15±7</td>
<td>8±3*</td>
<td>16±7</td>
<td>11±6**</td>
</tr>
<tr>
<td>AHI (/h sleep)</td>
<td>18±10</td>
<td>7±5**</td>
<td>16±8</td>
<td>9±7 **</td>
</tr>
<tr>
<td>MinSatO₂ (%)</td>
<td>86±4*</td>
<td>88±3*</td>
<td>86±4</td>
<td>87±5</td>
</tr>
</tbody>
</table>

BMI Body mass index, ESS Epworth sleepiness scale, MAI micro-arousal index, AHI apnea–hypopnea index, MinSatO₂ minimum oxygen saturation, FLQ Fletcher and Luckett questionnaire, SF36 SF 36 inventory for quality of life, FC functional capacity, LPhA limitation due to physical aspects, GSH general state of health, V vitality, SA social aspect, LEA limitation by emotional aspects, M mental health, MAD mandibular advancement device

* p<0.05 difference between baseline and at maximum mandibular advancement in PT group
** p<0.05 difference between baseline and at maximum mandibular advancement in ST group

Fig. 5 Number of patients with persistent and temporary pain caused by TMD at baseline, two-thirds and maximal advancement of the MAD in placebo therapy group (PT) and support therapy (ST) groups (Chi-squared test). *p<0.05

Fig. 6 Average of the intensity of pain caused by TMD at the baseline and final MAD position in placebo therapy (PT) and support therapy (ST) groups (test “t” for independent and dependent samples)
In our previous investigation [46], the prevalence of TMD was high (52%) in the OSAS population referred for MAD therapy. Of the individuals who showed TMD, 90% had myofascial masticatory muscles pain, and in 65% of those, joint pain was present. In 75% of the patients, the impact of TMD pain was of low intensity and low disability. Petit and colleagues [10] reported an active TMJ disorder was present in only 2% of patients.

The prevalence of side effects related to TMJ or masseter muscle pain was very different between studies [13, 40, 47]. As neither the degree of involvement nor the specificity of the TMD was determined, mild and severe cases were almost certainly lumped and assessed as one entity. The percentages of such side effects vary and can even be justified by the absence of a validated methodology with previous assessment of TMD [6–8]. Still, the authors did not use standardized classification criteria for the diagnosis of TMD prior to the treatment; therefore, it is possible that some of those 11 patients had TMD prior to the treatment. In 2001, Fritsch and collaborators [7] assessed side effects of the MAD in 22 individuals; mandibular pain was found to occur in nine patients (41%), and either stiffness or pain in the masseter was found in eight patients (36%). Prior systematic TMD evaluation was not assessed, similar to many other studies of MAD side effects [11–14]. This lack of diagnostic criteria for assessment, in our opinion, is responsible for such different findings. In the present investigation, the use of the RDC/TMD as a diagnostic instrument for TMD enabled us to assess the presence of TMD in OSAS patients prior to MAD treatment. Likewise, until the present report, there were no studies using a systematic protocol to evaluate TMD.

Yet another relevant issue is that none of the studies that assessed TMD as a side effect of MAD addressed alternative methods to minimize those effects and thus enabled continuation of the treatment [6–8]. Mandibular exercises, whether associated to other noninvasive treatment modalities (counseling and occlusion plates, for example) or not, have been used with satisfactory results in the control of pain caused by TMD. In those modalities, the observation period of patients submitted to exercises varied according to the protocol, but in general, good results were produced after 3 months [20–25]. In randomized controlled studies, mandibular exercises and counseling were compared to isolated counseling for the treatment of myofascial pain. The studies showed better results with the mandibular exercises; therefore, they suggest exercise therapy as a first choice intervention in muscular TMD [20, 21]. Also, passive mandibular exercises, used for the treatment of joint disease with [22] and without reduction [23], showed a significant reduction of pain after 6 months. Mandibular exercises also improve significantly joint sounds, compared to a control group [25]. Ueda and collaborators [48] used mandibular exercises combined with a MAD and found that this type of therapy did improve occlusal contact area and bite force. The authors related those findings to tooth movement and did not evaluate systematically the presence or absence of TMD. The current study is, to our knowledge, the first to use mandibular exercises with MAD therapy for patients with TMD and OSAS. Similarly to previous studies, we also found that mandibular exercises produced a significant improvement in TMD. Differently than those studies, our patients used the MAD therapy at night and the ST during the day.

The amount of mandibular protrusion prescribed as necessary for the treatment of OSAS varies between half and maximum mandibular advancement. The results collected herein show that when the MAD is positioned at two-thirds of the maximum mandibular advancement, the ST group presented less pain when compared to the PT group (three vs. nine patients, respectively), and the same distribution of pain prevalence was seen at maximum mandibular protrusion (four vs. ten, respectively). According to the RDC/TMD criteria, pain intensity decreased from pre-treatment to final mandibular protrusion only in the ST group. Contrarily, the PT group showed a slight increase in pain at the end of treatment. It is important to notice that the amount of mandibular protrusion did not differ between the groups, which allow us to infer that the amount of mandibular protrusion had no influence in the final results.

Data confirms the efficacy of ST in OSAS/TMD patients treated with a MAD. As yet, the available literature does not report that exercise aids the treatment of OSAS for patients with concomitant TMD.

Important studies have assessed pain as a factor for poor compliance to MAD; these studies showed that in a period of 3–7 months of follow-up, compliance rates vary from 68% to 100% [1, 45]. As for compliance to the MAD...
therapy in this investigation, no significant difference was
found between the groups in the baseline conditions (76% vs.
88% in the PT and ST groups, respectively). However,
after MAD advancement, higher adherence in the ST group
was observed (68% vs. 92% for PT and ST, respectively). It
can thus be inferred that mandible exercises most likely leads
to higher compliance to the use of a MAD in OSAS patients.

Although the results of the current investigation are
significant and might change indications and add exercises
to the management of patients in MAD therapy, clinical trials
poses challenges and some limitations to the study must be
taken into account. First, the number of patients was small,
and the RDC/TMD diagnosis was carried out by only one
examiner. Larger samples are necessary, and ideally, two
investigators would evaluate intra- and inter-observer biases.
Second, because of the nature of the intervention, the
patients would have been aware of the study allocation and
may have inadvertently unblended the investigators. As the
main outcome measures in this study were subjective, the
potential for investigator bias is an important consideration.
Third, because there is no objective instrument to assess MAD
compliance, we have recorded compliance subjectively by
means of a diary, which has been shown to overestimate the
hours of use. Another limitation of the present study was that
exercises were not supervised; adherence to the exercise
protocol was also recorded only by means of a diary. The
follow-up period of 120 days is relatively short and thus, it is
not possible to draw conclusion about the long-term effec-
tiveness of intervention. Finally, the MAD advancement
protocol used in the present study does not match the
traditional protocol. Our patients started at 50% advancement,
instead of the 60% to 75% advancements stated in the
literature. We believe that this was not important to our results,
as we had a controlled placebo group. The exclusion of
patients with mandibular protrusion of less than 5 mm or
limited mouth opening would have excluded patients with
more significant forms of TMD and limits the generalizability
of the results. In addition, this study did not recruit obese
patients or those with severe OSAS further limiting the
generalizability of the findings for these patients. However,
further studies are necessary to evaluate the ST under
traditional advancement protocols.

The fact of MAD being contraindicated in presence of
TMD is still controversial. There is one paper in the literature
stating short-term benefits of MAD on bruxism, which
is commonly associated with TMD. Despite of this, to our
knowledge, most papers available in Pubmed, have stated
that moderate to severe TMJ problems or an inadequate
protrusive ability may be contraindications to MAD therapy
[3, 10, 45]. These conflicting positions might be related to
the term TMDs, which we understand is not specific.
Although, in this research field the RDC criteria are until
now, in our opinion, the best research tool available. Still, we
believe that once better assessments tools are available
further studies are necessary. The fact that we have evaluated
only one type of MAD also configures a limitation of this
study, and therefore similar studies with most commonly
used appliances such as Klearway, Herbist, and PM
Positioner are necessary for our data to be generalized.

Despite some limitations, the results of the present study
allow us to suggest that OSAS patients who are referred for
MAD therapy require a specific assessment of TMD. Our
results also demonstrate that the contraindication of MAD for
the treatment of OSAS should be reexamined and that
mandibular exercises, when adopted as ST, can be influential
in decreasing pain and increasing MAD compliance in the
120 days of treatment in this study. Although the positive
result of ST in patients treated in this study, severe functional
limitations for TMD should be evaluated carefully. These
conditions have yet to be primarily treated for TMD.

Acknowledgements The authors would like to thank the Fundacao
de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, number
2006/04488–4), the FAPESP-Centros de Pesquisa, Inovação e Difusão
(CEPID), and the Associaacao Fundo de Incentivo a Psicofarmacologia
(AFIP) for their support and funding. Sergio Tufik and Lia Rita
Azeredo Bittencourt are principal investigators of FAPESP and
researchers of Conselho Nacional de Desenvolvimento Cientifico e
Tecnologico.

References

therapy improves symptoms in obstructive sleep apnea: a
randomized, controlled trial. Am J Respir Crit Care Med
166:743–748
3. Ferguson KA, Cartwright R, Rogers R, Schmidt-Nowara W
(2006) Oral appliances for snoring and obstructive sleep apnea:
a review. Sleep 29:244–262
sleep-disordered breathing. Sleep Breath 11:1–22
5. Kushida CA, Morgenthaler TI, Littner MR, Alessi CA, Bailey D,
Coleman J Jr, Friedman L, Hirshkowitz M, Kapan S, Kram M,
the treatment of snoring and obstructive sleep apnea with oral
EW (2000) A randomized controlled crossover trial of two
appliances for sleep apnea treatment. Am J Respir Crit Care Med
162:246–251
mandibular advancement devices for sleep apnea treatment. Am J
Respir Crit Care Med 164:813–818
(2002) Mandibular advancement appliances and obstructive sleep
apnoea: a randomized clinical trial. Eur J Orthod 24:251–262
9. Almeida FR, Bittencourt LR, de Almeida CI, Tsuiki S, Lowe AA,
Tufik S (2002) Effects of mandibular posture on obstructive sleep
apnea severity and the temporomandibular joint in patients fitted
with an oral appliance. Sleep 25:507–513


